{"id":"lucentis","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[{"effect":"Conjunctival hemorrhage","drugRate":"47%","severity":"common","organSystem":""},{"effect":"Cataract","drugRate":"28%","severity":"common","organSystem":""},{"effect":"Eye pain","drugRate":"17%","severity":"common","organSystem":""},{"effect":"Intraocular pressure increased","drugRate":"18%","severity":"common","organSystem":""},{"effect":"Vitreous detachment","drugRate":"11%","severity":"common","organSystem":""},{"effect":"Vitreous floaters","drugRate":"10%","severity":"common","organSystem":""},{"effect":"Foreign body sensation in eyes","drugRate":"10%","severity":"common","organSystem":""},{"effect":"Intraocular inflammation","drugRate":"4%","severity":"common","organSystem":""}],"contraindications":["Eye infection"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"Endophthalmitis","drugRate":"0.1%","severity":"serious"},{"effect":"Rhegmatogenous retinal detachment","drugRate":"0.1%","severity":"serious"},{"effect":"Iatrogenic traumatic cataract","drugRate":"0.1%","severity":"serious"},{"effect":"Thromboembolic events","drugRate":"","severity":"serious"},{"effect":"Fatal events in patients with DME and DR at baseline","drugRate":"","severity":"serious"},{"effect":"Tear of retinal pigment epithelium","drugRate":"","severity":"serious"},{"effect":"Wound healing complications","drugRate":"","severity":"serious"},{"effect":"Iritis","drugRate":"","severity":"serious"},{"effect":"Vitritis","drugRate":"","severity":"serious"}]},"trials":[],"_chembl":{"chemblId":"CHEMBL1201825","moleculeType":"Antibody"},"aliases":["Ranibizumab","ranibizumab","Aqueous Tap","Reference Product","Ranibizumab Injection"],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Lucentis","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:50:17.344611+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:50:23.415230+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lucentis","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:50:23.618966+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Vascular endothelial growth factor A inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:50:24.988500+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201825/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:50:24.639245+00:00"}},"offLabel":[],"timeline":[],"_dailymed":{"setId":"de4e66cc-ca05-4dc9-8262-e00e9b41c36d","title":"LUCENTIS (RANIBIZUMAB) INJECTION, SOLUTION [GENENTECH, INC.]"},"ecosystem":[],"mechanism":{"target":"Vascular endothelial growth factor A"},"_scrapedAt":"2026-03-27T23:53:34.897Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:50:26.257845+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Age related macular degeneration","diseaseId":"age-related-macular-degeneration","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Branch retinal vein occlusion with macular edema","diseaseId":"branch-retinal-vein-occlusion-with-macular-edema","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Central retinal vein occlusion with macular edema","diseaseId":"central-retinal-vein-occlusion-with-macular-edema","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Choroidal retinal neovascularization","diseaseId":"choroidal-retinal-neovascularization","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Diabetic retinopathy","diseaseId":"diabetic-retinopathy","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Exudative age-related macular degeneration","diseaseId":"exudative-age-related-macular-degeneration","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Macular edema due to diabetes mellitus","diseaseId":"macular-edema-due-to-diabetes-mellitus","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Retinopathy of prematurity","diseaseId":"retinopathy-of-prematurity","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07007065","phase":"PHASE3","title":"Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-11-05","conditions":"Neovascular Age-related Macular Degeneration","enrollment":561},{"nctId":"NCT06176352","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2024-03-06","conditions":"Choroidal Neovascularization Secondary to Pathologic Myopia","enrollment":280},{"nctId":"NCT05476926","phase":"","title":"A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-11-21","conditions":"Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion","enrollment":6000},{"nctId":"NCT05217680","phase":"PHASE3","title":"Clinical Study to Evaluate PRO-169 for Diabetic Macular Edema","status":"COMPLETED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2021-05-24","conditions":"Diabetic Macular Edema","enrollment":510},{"nctId":"NCT04853251","phase":"PHASE4","title":"A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)","status":"RECRUITING","sponsor":"Genentech, Inc.","startDate":"2021-12-14","conditions":"Neovascular Age-related Macular Degeneration","enrollment":188},{"nctId":"NCT04108156","phase":"PHASE3","title":"A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2019-09-30","conditions":"Diabetic Macular Edema","enrollment":634},{"nctId":"NCT04514653","phase":"PHASE2","title":"RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2020-08-25","conditions":"Neovascular Age-Related Macular Degeneration (nAMD)","enrollment":146},{"nctId":"NCT06847542","phase":"PHASE3","title":"A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-11-27","conditions":"Neovascular Age-related Macular Degeneration","enrollment":250},{"nctId":"NCT03683251","phase":"PHASE3","title":"Extension Study for the Port Delivery System With Ranibizumab (Portal)","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2018-09-20","conditions":"Neovascular Age-Related Macular Degeneration","enrollment":1000},{"nctId":"NCT04503551","phase":"PHASE3","title":"A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-08-10","conditions":"Diabetic Retinopathy","enrollment":174},{"nctId":"NCT04704921","phase":"PHASE2, PHASE3","title":"Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD","status":"RECRUITING","sponsor":"AbbVie","startDate":"2020-12-29","conditions":"AMD, nAMD, Wet Age-related Macular Degeneration","enrollment":630},{"nctId":"NCT04657289","phase":"PHASE3","title":"A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-07-14","conditions":"Neovascular Age-related Macular Degeneration (nAMD)","enrollment":451},{"nctId":"NCT07389577","phase":"PHASE3","title":"A Study to Compare JL14002 to Lucentis® in Subjects With Wet Age-related Macular Degeneration (wAMD)","status":"COMPLETED","sponsor":"Jecho Biopharmaceuticals Co., Ltd.","startDate":"2022-03-01","conditions":"Wet Age-related Macular Degeneration","enrollment":443},{"nctId":"NCT04567303","phase":"PHASE1, PHASE2","title":"Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-10-28","conditions":"Macular Degeneration","enrollment":177},{"nctId":"NCT05562947","phase":"PHASE3","title":"A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD)","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2024-06-17","conditions":"Neovascular Age-related Macular Degeneration, nAMD","enrollment":68},{"nctId":"NCT04690556","phase":"PHASE3","title":"Study to Compare Efficacy, Safety, and Immunogenicity of LUBT010 (Proposed Ranibizumab Biosimilar) and Lucentis® in Patients With Neovascular AMD","status":"COMPLETED","sponsor":"Lupin Ltd.","startDate":"2020-09-14","conditions":"Neovascular Age-related Macular Degeneration","enrollment":600},{"nctId":"NCT06957080","phase":"PHASE2, PHASE3","title":"A Study of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME","status":"ACTIVE_NOT_RECRUITING","sponsor":"EyeBiotech Ltd.","startDate":"2025-04-16","conditions":"Diabetic Macular Edema (DME)","enrollment":1054},{"nctId":"NCT05520177","phase":"PHASE3","title":"A Phase III Study for 601 Versus Ranibizumab in Patients With Vision Loss","status":"COMPLETED","sponsor":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","startDate":"2022-12-27","conditions":"Branch Retinal Vein Occlusion","enrollment":351},{"nctId":"NCT07269769","phase":"PHASE3","title":"A Clinical Trial Evaluating the Efficacy and Safety of Sanhuang Jingshiming Pills in the Treatment of nAMD","status":"NOT_YET_RECRUITING","sponsor":"Tasly Pharmaceutical Group Co., Ltd","startDate":"2026-01-01","conditions":"AMD","enrollment":450},{"nctId":"NCT05439629","phase":"PHASE3","title":"Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration","status":"COMPLETED","sponsor":"Bio-Thera Solutions","startDate":"2022-07-07","conditions":"Neovascular (Wet) Age-related Macular Degeneration","enrollment":488},{"nctId":"NCT07258108","phase":"PHASE2","title":"Lucentis Plus Tagolimumab in PD-L1+, HR+/HER2- Advanced Breast Cancer After CDK4/6 Inhibitors","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-11-21","conditions":"Breast Cancer","enrollment":35},{"nctId":"NCT00527475","phase":"PHASE2","title":"Ranibizumab and Reduced Fluence PDT for AMD","status":"COMPLETED","sponsor":"Texas Retina Associates","startDate":"2007-05","conditions":"Macular Degeneration","enrollment":60},{"nctId":"NCT07249216","phase":"NA","title":"Identification of Molecular Signals in Vitreous Humor Associated With Suboptimal Response to Vascular Endothelial Growth Factor (VEGF) Inhibition in Neovascular Age-related Macular Degeneration (nAMD) Within a Clinical Trial Setting","status":"RECRUITING","sponsor":"Singapore National Eye Centre","startDate":"2025-07-18","conditions":"Age Related Macular Degeneration","enrollment":117},{"nctId":"NCT06952452","phase":"PHASE3","title":"Pharmacogenomics of antiVEGF in Patients With Age-Associated Macular Degeneration (AMD)","status":"RECRUITING","sponsor":"Parc de Salut Mar","startDate":"2022-11-18","conditions":"Wet Age-related Macular Degeneration","enrollment":630},{"nctId":"NCT03161652","phase":"PHASE2","title":"Effect of Levosulpiride on Retinal Alterations in Patients With Diabetic Retinopathy and Diabetic Macular Edema","status":"RECRUITING","sponsor":"Carmen Clapp","startDate":"2017-05-24","conditions":"Diabetic Macular Edema, Diabetic Retinopathy","enrollment":120},{"nctId":"NCT05151731","phase":"PHASE2","title":"A Study to Investigate Vamikibart (RO7200220) in Diabetic Macular Edema","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2021-12-31","conditions":"Diabetic Macular Edema","enrollment":394},{"nctId":"NCT05151744","phase":"PHASE2","title":"A Study to Investigate Vamikibart (RO7200220) in Combination With Ranibizumab in Diabetic Macular Edema","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2021-12-17","conditions":"Diabetic Macular Edema","enrollment":187},{"nctId":"NCT05407636","phase":"PHASE3","title":"Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD","status":"RECRUITING","sponsor":"AbbVie","startDate":"2022-01-13","conditions":"AMD, nAMD, Wet Age-related Macular Degeneration","enrollment":660},{"nctId":"NCT06985706","phase":"PHASE3","title":"Anti-vascular Endothelial Growth Factor (Anti-VEGF) Monotherapy vs Anti-VEGF Followed by Subthreshold Micropulse Laser for Treating Severe Diabetic Macular Oedema When the Central Retina Goes <400 Microns","status":"RECRUITING","sponsor":"Belfast Health and Social Care Trust","startDate":"2025-05-19","conditions":"Severe Diabetic Macular Oedema","enrollment":264},{"nctId":"NCT03832179","phase":"PHASE4","title":"Steroid vs. Anti-vascular Endothelial Growth Factor for Diabetic Macular Edema Prior to Phacoemulsification","status":"COMPLETED","sponsor":"Bay Area Retina Associates","startDate":"2018-11-15","conditions":"Diabetic Macular Edema, Cataract","enrollment":16},{"nctId":"NCT06234514","phase":"PHASE4","title":"Manage Macular Cystoid Edema With Retinal Vein Obstruction Using Traditional Chinese Medicine and Ranibizumab","status":"COMPLETED","sponsor":"Dongyang People's Hospital","startDate":"2023-01-01","conditions":"Macular Cystoid Edema","enrollment":111},{"nctId":"NCT06571045","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME","status":"ACTIVE_NOT_RECRUITING","sponsor":"EyeBiotech Ltd.","startDate":"2024-08-07","conditions":"Diabetic Macular Edema (DME)","enrollment":984},{"nctId":"NCT02243878","phase":"PHASE3","title":"Stereotactic Radiotherapy for Wet AMD (STAR)","status":"COMPLETED","sponsor":"King's College Hospital NHS Trust","startDate":"2014-12","conditions":"Neovascular (Wet) Age-related Macular Degeneration (AMD)","enrollment":411},{"nctId":"NCT04757610","phase":"PHASE3","title":"OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD)","status":"TERMINATED","sponsor":"Opthea Limited","startDate":"2021-03-12","conditions":"Neovascular Age-related Macular Degeneration","enrollment":986},{"nctId":"NCT05304949","phase":"","title":"Regulatory PMS Study for Lucentis® in Patients With Retinopathy of Prematurity","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2022-06-22","conditions":"Retinopathy of Prematurity","enrollment":69},{"nctId":"NCT04667910","phase":"PHASE2","title":"601 Versus Ranibizumab in Patients With Central Retinal Vein Occlusion (CRVO)","status":"COMPLETED","sponsor":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","startDate":"2021-01-27","conditions":"Central Retinal Vein Occlusion","enrollment":60},{"nctId":"NCT04667897","phase":"PHASE2","title":"601 Versus Ranibizumab in Patients With Branch Retinal Vein Occlusion (BRVO)","status":"COMPLETED","sponsor":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","startDate":"2021-01-28","conditions":"Branch Retinal Vein Occlusion","enrollment":60},{"nctId":"NCT03362190","phase":"PHASE2","title":"ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD)","status":"COMPLETED","sponsor":"Ophthotech Corporation","startDate":"2017-10-11","conditions":"Neovascular Age-related Macular Degeneration","enrollment":64},{"nctId":"NCT07009574","phase":"","title":"The Treatment Burden of Myopic Choroidal Neovascularization","status":"NOT_YET_RECRUITING","sponsor":"Policlinico Gaspare Rodolico - San Marco Catania","startDate":"2025-06-01","conditions":"Myopic Choroidal Neovascularisation, Anti-VEGF Treatment, Burden","enrollment":100},{"nctId":"NCT06305416","phase":"PHASE3","title":"A Efficacy and Safety Study of Ranibizumab 10mg/ml Injection (Incepta) in Patients With Diabetic Macular Edema","status":"RECRUITING","sponsor":"Incepta Pharmaceuticals Ltd","startDate":"2024-03-30","conditions":"Diabetic Macular Edema, Diabetic Retinopathy, Macular Edema","enrollment":70},{"nctId":"NCT03585556","phase":"PHASE1","title":"AAVCAGsCD59 for the Treatment of Wet AMD","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-09-13","conditions":"Wet Age-related Macular Degeneration","enrollment":25},{"nctId":"NCT04444492","phase":"PHASE3","title":"Combination of Ranibizumab and Targeted Laser Photocoagulation","status":"RECRUITING","sponsor":"University of Giessen","startDate":"2020-08-25","conditions":"Central Retinal Vein Occlusion With Macular Edema","enrollment":110},{"nctId":"NCT05576792","phase":"","title":"A 24-week Study Evaluating the Effectiveness and Safety of Lucentis® 0.2mg in Retinopathy of Prematurity Participants in China","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2023-01-13","conditions":"Retinopathy of Prematurity","enrollment":62},{"nctId":"NCT05003245","phase":"PHASE3","title":"Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD","status":"COMPLETED","sponsor":"Shanghai Henlius Biotech","startDate":"2021-11-01","conditions":"Age Related Macular Degeneration","enrollment":407},{"nctId":"NCT02397954","phase":"PHASE2","title":"A Study to Establish the Safety and Tolerability of Zimura™ (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)","status":"COMPLETED","sponsor":"Ophthotech Corporation","startDate":"2015-03-12","conditions":"Idiopathic Polypoidal Choroidal Vasculopathy","enrollment":4},{"nctId":"NCT03844074","phase":"PHASE3","title":"A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Outlook Therapeutics, Inc.","startDate":"2018-10-01","conditions":"Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration","enrollment":61},{"nctId":"NCT03834753","phase":"PHASE3","title":"A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Outlook Therapeutics, Inc.","startDate":"2019-06-25","conditions":"Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration","enrollment":228},{"nctId":"NCT05571267","phase":"PHASE2","title":"Safety Study of Zimura in Combination With Anti-VEGF Therapy in Patients With Neovascular AMD","status":"TERMINATED","sponsor":"IVERIC bio, Inc.","startDate":"2016-10-20","conditions":"Neovascular Age-Related Macular Degeneration","enrollment":1},{"nctId":"NCT00709527","phase":"PHASE1","title":"ARC1905 (Anti-C5 Aptamer) Given With Lucentis 0.5 mg In People With Neovascular Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"Ophthotech Corporation","startDate":"2008-10-16","conditions":"Neovascular Age-Related Macular Degeneration","enrollment":60},{"nctId":"NCT06190093","phase":"PHASE3","title":"A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects with Neovascular Age-related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Outlook Therapeutics, Inc.","startDate":"2024-01-24","conditions":"Neovascular Age-related Macular Degeneration, Age-Related Macular Degeneration, Wet Macular Degeneration","enrollment":400},{"nctId":"NCT06841250","phase":"","title":"Early Changes in OCT Biomarkers After the First Intravitreal Anti-VEGF Injection in Treatment-naïve DME","status":"ENROLLING_BY_INVITATION","sponsor":"Sohag University","startDate":"2025-01-16","conditions":"Early OCT Biomarker Changes in Response to Anti-VEGF","enrollment":50},{"nctId":"NCT05640895","phase":"","title":"Intravitreal Injection Site and Perceived Pain","status":"COMPLETED","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2022-11-14","conditions":"Pain","enrollment":53},{"nctId":"NCT06271330","phase":"","title":"Multicenter Real-life Observational Study Switched Aflibercept or Ranibizumab to Faricimab in Patients With AMD.","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2024-04-01","conditions":"Age-related Macular Degeneration","enrollment":100},{"nctId":"NCT06771271","phase":"PHASE1","title":"A Study to Investigate RO7200220 as Monotherapy and in Combination With Ranibizumab in Participants With Diabetic and Uveitic Macular Edema","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2019-07-22","conditions":"Diabetic Macular Edema, Uveitic Macular Edema","enrollment":85},{"nctId":"NCT05461339","phase":"PHASE3","title":"TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration","status":"ACTIVE_NOT_RECRUITING","sponsor":"BioDlink Biopharm Co., Ltd.","startDate":"2022-06-28","conditions":"Neovascular Age-related Macular Degeneration","enrollment":488},{"nctId":"NCT04740671","phase":"PHASE3","title":"A Phase 3 Study to Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD","status":"COMPLETED","sponsor":"Shanghai Henlius Biotech","startDate":"2021-07-01","conditions":"Age Related Macular Degeneration","enrollment":410},{"nctId":"NCT06176963","phase":"PHASE2","title":"A Study to Evaluate the Usability of the SB11 PFS in Subjects With Wet AMD or Macular Oedema Secondary to RVO","status":"COMPLETED","sponsor":"Samsung Bioepis Co., Ltd.","startDate":"2023-11-21","conditions":"Neovascular Age-related Macular Degeneration, Macular Edema, Retinal Vein Occlusion","enrollment":34},{"nctId":"NCT06708624","phase":"PHASE4","title":"Ocular Safety and Usability Study for FYB201 PFS","status":"COMPLETED","sponsor":"Formycon AG","startDate":"2024-06-11","conditions":"Age-Related Macular Degeneration, Branch Retinal Vein Occlusion with Macular Edema, Central Retinal Vein Occlusion with Macular Edema","enrollment":31},{"nctId":"NCT05861466","phase":"PHASE4","title":"Comparative Study Between IVI of Ranibizumab with and Without Prior ACP in Patients with DME Using OCT-A","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2023-01-01","conditions":"Diabetic Macular Edema","enrollment":102},{"nctId":"NCT02669953","phase":"","title":"Aflibercept in Recurrent or Persistent CNV","status":"RECRUITING","sponsor":"Medical University of Vienna","startDate":"2015-12","conditions":"Age Related Macular Degeneration, Intravitreal Injections, Diabetic Macular Edema","enrollment":80},{"nctId":"NCT02302079","phase":"PHASE2","title":"A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema (DME)","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2015-01-12","conditions":"Diabetes Mellitus, Diabetic Macular Edema","enrollment":96},{"nctId":"NCT02387957","phase":"PHASE2","title":"A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)","status":"TERMINATED","sponsor":"Ophthotech Corporation","startDate":"2016-04-26","conditions":"Age-Related Macular Degeneration","enrollment":63},{"nctId":"NCT01940900","phase":"PHASE3","title":"A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy","status":"TERMINATED","sponsor":"Ophthotech Corporation","startDate":"2013-08","conditions":"Age-Related Macular Degeneration","enrollment":627},{"nctId":"NCT01944839","phase":"PHASE3","title":"A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy","status":"TERMINATED","sponsor":"Ophthotech Corporation","startDate":"2013-08","conditions":"Age-Related Macular Degeneration","enrollment":619},{"nctId":"NCT03709745","phase":"PHASE4","title":"Eylea and Lucentis for Macular Edema in Branch Retinal Vein Occlusion","status":"COMPLETED","sponsor":"St. Erik Eye Hospital","startDate":"2018-10-18","conditions":"Branch Retinal Vein Occlusion with Macular Edema","enrollment":110},{"nctId":"NCT03630315","phase":"PHASE1","title":"CLN-0046: Treatment of AMD Subjects With OTX-TKI","status":"COMPLETED","sponsor":"Ocular Therapeutix, Inc.","startDate":"2019-02-18","conditions":"Neovascular Age-related Macular Degeneration","enrollment":29},{"nctId":"NCT03927690","phase":"PHASE2","title":"Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-05-24","conditions":"Diabetic Macular Edema","enrollment":91},{"nctId":"NCT04662944","phase":"","title":"A Non-interventional Study to Assess the Influence of Automated Optical Coherence Tomography Image Enrichment With Segmentation Information on Disease Activity Assessment in Patients Treated With Licensed Anti- VEGF Injections","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-02-23","conditions":"Neovascular Age-Related Macular Degeneration","enrollment":494},{"nctId":"NCT05211804","phase":"","title":"Mechanisms of Retinal Revascularization and Clinical Indicators of Neovascular AMD Relapse","status":"COMPLETED","sponsor":"Sorlandet Hospital HF","startDate":"2022-02-08","conditions":"Wet Macular Degeneration","enrollment":31},{"nctId":"NCT00930189","phase":"PHASE2, PHASE3","title":"Comparative Study With Photodynamic Therapy And Triamcinolone Versus Photodynamic Therapy, Triamcinolone And Ranibizumab In Patients With Subfoveal Choroidal Neovascularization","status":"WITHDRAWN","sponsor":"Asociación para Evitar la Ceguera en México","startDate":"2006-04","conditions":"Subfoveal Choroidal Neovascularization","enrollment":""},{"nctId":"NCT04884399","phase":"PHASE1","title":"Phase I Study to Compare CMAB818 Injection and Lucentis® in Patients With Wet AMD","status":"COMPLETED","sponsor":"Shanghai Biomabs Pharmaceutical Co., Ltd.","startDate":"2021-06-03","conditions":"Wet Age-related Macular Degeneration","enrollment":24},{"nctId":"NCT04075136","phase":"PHASE4","title":"Optical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy","status":"WITHDRAWN","sponsor":"Wake Forest University Health Sciences","startDate":"2023-03-30","conditions":"Exudative Age Related Macular Degeneration","enrollment":""},{"nctId":"NCT01089517","phase":"PHASE2","title":"A Safety and Efficacy Study of E10030 (Anti-PDGF Pegylated Aptamer) Plus Lucentis for Neovascular Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"Ophthotech Corporation","startDate":"2010-03","conditions":"Age-Related Macular Degeneration","enrollment":449},{"nctId":"NCT02214628","phase":"PHASE2","title":"Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF BB) Regimen Administered in Combination With Anti-VEGF Therapy to Study Sub-Retinal Fibrosis in Neovascular AMD","status":"TERMINATED","sponsor":"Ophthotech Corporation","startDate":"2014-07","conditions":"Age-related Macular Degeneration","enrollment":101},{"nctId":"NCT00569140","phase":"PHASE1","title":"A Phase 1, Safety, Tolerability and Pharmacokinetic Profile of Intravitreous Injections of E10030 (Anti-PDGF Pegylated Aptamer) in Subjects With Neovascular Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"Ophthotech Corporation","startDate":"2007-12","conditions":"Age-related Macular Degeneration","enrollment":18},{"nctId":"NCT06231121","phase":"","title":"Switching to Faricimab in Neovascular Age-related Macular Degeneration Resistant to Both Aflibercept and Ranibizumab","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2023-12-01","conditions":"Neovascular Age-related Macular Degeneration","enrollment":13},{"nctId":"NCT05126966","phase":"PHASE3","title":"A Study Of The Effectiveness And Safety Of A 36-Week Refill Regimen For The Port Delivery System With Ranibizumab Vs Aflibercept Treat & Extend In Subjects With Neovascular Age-Related Macular Degeneration","status":"WITHDRAWN","sponsor":"Hoffmann-La Roche","startDate":"2023-12-29","conditions":"Neovascular Age-Related Macular Degeneration","enrollment":""},{"nctId":"NCT06205979","phase":"EARLY_PHASE1","title":"Relationship Between Dyslipidemia and The Response of Diabetic Macular Edema to Intravitreal Injection of Anti Vascular Endothelial Growth Factor Agents","status":"UNKNOWN","sponsor":"Sohag University","startDate":"2023-12-12","conditions":"Diabetic Macular Edema","enrollment":50},{"nctId":"NCT06179030","phase":"","title":"Systemic and Local Inflammatory Biomarkers in the Treatment of Refractory Diabetic Macular Edema","status":"COMPLETED","sponsor":"Saglik Bilimleri Universitesi","startDate":"2022-05-01","conditions":"Diabetic Macular Edema, Inflammation","enrollment":80},{"nctId":"NCT06173245","phase":"NA","title":"Subfoveal Choroidal Thickness and Visual Acuity After Intravitreal Injection of Ranibizumab in Diabetic Retinopathy","status":"COMPLETED","sponsor":"Egyptian Biomedical Research Network","startDate":"2021-02-01","conditions":"Subfoveal Choroidal Thickness, Intravitreal, Ranibizumab","enrollment":50},{"nctId":"NCT03805100","phase":"PHASE3","title":"Comparing the Efficacy and Safety of Biosimilar Candidate Xlucane Versus Lucentis® in Patients With nAMD","status":"COMPLETED","sponsor":"Xbrane Biopharma AB","startDate":"2019-04-19","conditions":"Macular Degeneration","enrollment":582},{"nctId":"NCT04140448","phase":"","title":"Ultra-wide-field Fluorescein Angiography in Patients With Macular Edema Secondary to Retinal Vein Occlusion","status":"UNKNOWN","sponsor":"Renmin Hospital of Wuhan University","startDate":"2023-10-09","conditions":"Retinal Vein Occlusion, Macular Edema","enrollment":60},{"nctId":"NCT03784443","phase":"PHASE2, PHASE3","title":"Combined Ranibizumab and Iluvien for Diabetic Macular Oedema","status":"WITHDRAWN","sponsor":"Imperial College London","startDate":"2019-09-01","conditions":"Diabetic Macular Edema, Diabetes","enrollment":""},{"nctId":"NCT05080803","phase":"","title":"Diabetic Macular Edema: Relevance of Staging Progression on Therapeutic Outcome","status":"COMPLETED","sponsor":"European School of Advanced Studies in Ophthalmology","startDate":"2021-06-01","conditions":"Diabetic Macular Edema","enrollment":608},{"nctId":"NCT04667039","phase":"PHASE3","title":"Efficacy, Safety, pharmacokinetiсs, Immunogenicity of GNR-067 and Lucentis®","status":"UNKNOWN","sponsor":"AO GENERIUM","startDate":"2022-03-20","conditions":"Age Related Macular Degeneration (ARMD)","enrollment":408},{"nctId":"NCT02511067","phase":"PHASE2","title":"Ranibizumab for Edema of the mAcula in Diabetes: Protocol 4 With Tocilizumab: The READ-4 Study","status":"WITHDRAWN","sponsor":"University of Nebraska","startDate":"2016-10-01","conditions":"Diabetic Macular Edema","enrollment":""},{"nctId":"NCT02207712","phase":"NA","title":"Noctura400 Treatment for Diabetic Retinopathy (CANDLE)","status":"TERMINATED","sponsor":"PolyPhotonix Medical","startDate":"2014-11","conditions":"Diabetic Macular Oedema","enrollment":252},{"nctId":"NCT05138029","phase":"PHASE3","title":"Study on Precision Treatment of Diabetic Retinopathy Macular Edema Guided by Real-time OCT During Operation","status":"UNKNOWN","sponsor":"Affiliated Hospital of Nantong University","startDate":"2021-11-15","conditions":"Diabetic Retinopathy","enrollment":60},{"nctId":"NCT02623426","phase":"PHASE3","title":"Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial","status":"COMPLETED","sponsor":"JHSPH Center for Clinical Trials","startDate":"2017-03-09","conditions":"Uveitis, Macular Edema","enrollment":194},{"nctId":"NCT05815212","phase":"","title":"Ranibizumab 0.5 mg for Diabetic Macular Edema With Initial Intensive Treatment in the Real World Clinical Setting in Korea (Rising K)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-06-11","conditions":"Diabetic Macular Edema","enrollment":87},{"nctId":"NCT00606138","phase":"PHASE1, PHASE2","title":"Ranibizumab for Treatment of Persistent Diabetic Neovascularization Assessed by Wide-Field Imaging","status":"COMPLETED","sponsor":"Rush University Medical Center","startDate":"2008-01","conditions":"Proliferative Diabetic Retinopathy","enrollment":9},{"nctId":"NCT02559180","phase":"PHASE4","title":"Treatment of Diabetic Macular Edema With Aflibercept in Subjects Previously Treated With Ranibizumab or Bevacizumab","status":"COMPLETED","sponsor":"Rishi Singh","startDate":"2015-10","conditions":"Diabetic Retinopathy, Macular Edema","enrollment":20},{"nctId":"NCT04991350","phase":"PHASE4","title":"Effect of Ranibizumab Versus Bevacizumab on the Macular Perfusion in Diabetic Macular Edema","status":"TERMINATED","sponsor":"Cairo University","startDate":"2021-11-26","conditions":"Diabetic Macular Edema, Macular Ischemia, Diabetic Retinopathy","enrollment":5},{"nctId":"NCT05480293","phase":"PHASE3","title":"This Study Will Compare the Efficacy and Safety of SCT510A Administered by Intravitreal Injection (IVT) With Ranibizumab in Patients With wAMD","status":"UNKNOWN","sponsor":"Sinocelltech Ltd.","startDate":"2023-02-14","conditions":"Wet Age-related Macular Degeneration","enrollment":446},{"nctId":"NCT02640664","phase":"PHASE3","title":"Rainbow Extension Study","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-06-16","conditions":"Retinopathy of Prematurity (ROP)","enrollment":180},{"nctId":"NCT05716932","phase":"","title":"Focal Laser Single Intravitreal Ranibizumab Retinal Artery Macroaneurysm.","status":"COMPLETED","sponsor":"Dar El Oyoun Hospital","startDate":"2022-12-22","conditions":"Retinal Artery Macroaneurysm","enrollment":14},{"nctId":"NCT05701124","phase":"PHASE3","title":"Intravitreal Ranibizumab Injection for Aggressive Versus Type 1 Prethreshold Retinopathy of Prematurity","status":"COMPLETED","sponsor":"Zagazig University","startDate":"2020-11-20","conditions":"Retina Disease, Retinopathy of Prematurity, Ranibizumab","enrollment":30},{"nctId":"NCT03963596","phase":"NA","title":"Antiangiogenic Therapy of Choroidal Neovascularisation Associated With Myopia","status":"COMPLETED","sponsor":"The Filatov Institute of Eye Diseases and Tissue Therapy","startDate":"2018-03-27","conditions":"Pathologic Myopia","enrollment":122},{"nctId":"NCT05678517","phase":"","title":"Seven-year Outcomes Following Intensive Anti-VEGF Therapy in Wet AMD","status":"COMPLETED","sponsor":"Semmelweis University","startDate":"2010-01-01","conditions":"Age-Related Macular Degeneration","enrollment":47},{"nctId":"NCT03690947","phase":"PHASE4","title":"Combination of Intravitreal Ranibizumab With or Without Micropulse Laser for the Treatment of DME","status":"COMPLETED","sponsor":"Beijing Hospital","startDate":"2018-10-01","conditions":"Diabetic Macular Edema","enrollment":72}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"chemblId":"CHEMBL1201825"},"formularyStatus":[],"_approvalHistory":[{"date":"20140227","type":"SUPPL","sponsor":"GENENTECH","applicationNumber":"BLA125156"},{"date":"20240215","type":"SUPPL","sponsor":"GENENTECH","applicationNumber":"BLA125156"},{"date":"20120810","type":"SUPPL","sponsor":"GENENTECH","applicationNumber":"BLA125156"},{"date":"20080423","type":"SUPPL","sponsor":"GENENTECH","applicationNumber":"BLA125156"},{"date":"20170415","type":"SUPPL","sponsor":"GENENTECH","applicationNumber":"BLA125156"},{"date":"20150206","type":"SUPPL","sponsor":"GENENTECH","applicationNumber":"BLA125156"},{"date":"20161122","type":"SUPPL","sponsor":"GENENTECH","applicationNumber":"BLA125156"},{"date":"20161013","type":"SUPPL","sponsor":"GENENTECH","applicationNumber":"BLA125156"},{"date":"20070426","type":"SUPPL","sponsor":"GENENTECH","applicationNumber":"BLA125156"},{"date":"20100519","type":"SUPPL","sponsor":"GENENTECH","applicationNumber":"BLA125156"},{"date":"20060630","type":"ORIG","sponsor":"GENENTECH","applicationNumber":"BLA125156"},{"date":"20130308","type":"SUPPL","sponsor":"GENENTECH","applicationNumber":"BLA125156"},{"date":"20120810","type":"SUPPL","sponsor":"GENENTECH","applicationNumber":"BLA125156"},{"date":"20180320","type":"SUPPL","sponsor":"GENENTECH","applicationNumber":"BLA125156"},{"date":"20130206","type":"SUPPL","sponsor":"GENENTECH","applicationNumber":"BLA125156"},{"date":"20141125","type":"SUPPL","sponsor":"GENENTECH","applicationNumber":"BLA125156"},{"date":"20170105","type":"SUPPL","sponsor":"GENENTECH","applicationNumber":"BLA125156"},{"date":"20100622","type":"SUPPL","sponsor":"GENENTECH","applicationNumber":"BLA125156"}],"developmentCodes":[],"ownershipHistory":[],"publicationCount":489,"therapeuticAreas":["Metabolic"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Lucentis","genericName":"Lucentis","companyName":"Santen Inc.","companyId":"santen-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":24,"withResults":6},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:50:26.257845+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}